🔍

JYOTHYLAB - Jyothy Labs

📊 NSE: JYOTHYLAB 🏢 Personal Care - Indian 📅 Last Updated: 12/14/2025 8:44

📢 Recent Corporate Announcements

Jyothy Labs to Meet Mirabilis Investment Trust on March 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Mar 2026, 04:56 PM

Jyothy Labs Limited has scheduled a one-on-one meeting with Mirabilis Investment Trust on March 12, 2026. This interaction is part of the company's regular engagement with institutional investors and analysts. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during this meeting. Investors are encouraged to review the latest investor presentation available on the company's official website for current business insights.

One-on-one meeting scheduled with Mirabilis Investment Trust on March 12, 2026.
Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
The schedule is subject to change based on exigencies from either the investor or the company.

💡 This is a routine investor interaction; no immediate action is required. Investors should monitor the company's website for any updated investor presentations following the meet.

Jyothy Labs to Meet Renaissance Investment Managers on March 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 12:43 PM

Jyothy Labs Limited has announced a scheduled one-on-one meeting with Renaissance Investment Managers on March 6, 2026. This disclosure is part of the company's routine regulatory compliance under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during this interaction. Such meetings are standard practice for listed companies to engage with institutional investors regarding publicly available information.

One-on-one meeting scheduled with Renaissance Investment Managers on March 6, 2026.
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
Latest investor presentation remains available on the company's official website for public access.

💡 No immediate action is required as this is a routine investor engagement. Investors may review the latest investor presentation on the company's website for current business performance insights.

Jyothy Labs Schedules One-on-One Meeting with Pari Washington for Feb 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Feb 2026, 02:44 PM

Jyothy Labs Limited has announced a scheduled one-on-one meeting with Pari Washington Company Advisors Pvt. Ltd on February 26, 2026. This disclosure is made in compliance with SEBI Regulation 30 regarding investor interactions. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the meeting. Investors are encouraged to review the latest investor presentation available on the company's official website for current business insights.

One-on-one meeting scheduled with Pari Washington Company Advisors Pvt. Ltd on February 26, 2026
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed
Latest investor presentation remains the primary source of shared information for the public

💡 No immediate action is required as this is a routine investor engagement. Investors should monitor for any subsequent corporate presentations that might provide updated business outlooks.

Jyothy Labs Schedules One-on-One Meeting with Mirae Asset Multicap Fund

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Feb 2026, 06:05 PM

Jyothy Labs Limited has informed the exchanges about a scheduled one-on-one meeting with Mirae Asset Multicap Fund on February 25, 2026. The meeting is part of the company's regular investor engagement process and will be attended by company representatives. The management has clarified that no unpublished price sensitive information (UPSI) will be shared during the discussion. This notification is a standard compliance requirement under SEBI Listing Obligations and Disclosure Requirements.

Meeting scheduled with Mirae Asset Multicap Fund for February 25, 2026
Interaction type is specified as a one-on-one meeting
Company confirms no Unpublished Price Sensitive Information (UPSI) will be shared
Notification issued on February 23, 2026, in compliance with SEBI Regulation 30

💡 No immediate action is required as this is a routine institutional meeting. Investors may review the latest investor presentation on the company's website for current business insights.

Jyothy Labs Q3 FY26: Revenue Up 5.1% to ₹740 Cr; Volume Growth Strong at 7.2%

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 12:24 PM

Jyothy Labs reported a 5.1% YoY revenue growth to ₹740 crores for Q3 FY26, supported by a healthy 7.2% volume growth. While Fabric Care and Personal Care segments performed well, the Dishwash segment saw a 1.3% value decline despite 7% volume growth due to aggressive pricing and promotions. Gross margins contracted by 330 bps to 46.5% because of rising input costs like LABSA and SLES, alongside MRP reductions. The company has divested its Bangladesh JV to focus on domestic growth and expects the Household Insecticide segment to turn around by FY27.

Revenue for Q3 FY26 stood at ₹740 crores with a volume growth of 7.2% and value growth of 5.1%.
Gross margin declined by 330 basis points to 46.5% due to raw material inflation and competitive pricing.
Fabric Care segment grew 9.2% in value, while Household Insecticides saw a 12.6% value growth driven by liquid vaporizers.
Dishwash segment volume grew 7% but value declined 1.3% due to higher grammage and price cuts.
Divested stake in Bangladesh JV (JKBL) with a loss of ₹4 crores to focus on core domestic and select export markets.

💡 Investors should focus on the company's ability to maintain volume momentum while navigating gross margin pressures from raw material volatility. The strategic shift in the Household Insecticide segment toward liquid vaporizers is a key monitorable for long-term profitability.

Jyothy Labs Releases Q3 FY2025-26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 06:52 PM

Jyothy Labs Limited has released the audio recording of its conference call held on February 9, 2026, regarding its financial performance for the quarter and nine months ended December 31, 2025. The call provided a platform for management to discuss un-audited financial results and the company's future outlook with analysts and institutional investors. This disclosure is a mandatory regulatory requirement under SEBI LODR Regulations. Investors can access the recording via the company's website to understand the nuances of the recent quarterly performance.

Audio recording of the Q3 FY2025-26 analyst call is now available for public access.
The call was conducted on February 9, 2026, following the announcement of December 2025 results.
Discussion included financial performance for the nine-month period ended December 31, 2025.
The recording covers management commentary on the 'way forward' and strategic initiatives.
Compliance filing made under Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements).

💡 Investors should listen to the recording to gain insights into management's commentary on volume growth and margin outlook. This is a routine disclosure and does not represent a new material event beyond the earnings release itself.

Jyothy Labs Q3 FY26: Revenue Up 5.1% to ₹740 Cr, Volume Growth Strong at 7.2%

🔵 WATCH ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 01:25 PM

Jyothy Labs reported a 5.1% YoY revenue growth for Q3 FY26, reaching ₹740 Crores, supported by a healthy volume growth of 7.2%. However, profitability faced headwinds as Gross Margins contracted to 46.5% from 49.8% due to commodity inflation and increased consumer offers. Operating EBITDA declined by 4.4% to ₹110.7 Crores, with margins dropping to 15.0% from 16.5% in the previous year. While Personal Care and Dishwashing segments grew double-digits, the Household Insecticides segment saw a marginal decline of 1.3%.

Revenue from operations increased 5.1% YoY to ₹740 Crores with 7.2% volume growth.
Gross Margin contracted by 330 basis points to 46.5% due to inflationary commodity trends.
PAT for the quarter stood at ₹81.1 Crores, representing a 7.2% decline compared to the same period last year.
Personal Care segment led growth at 12.6%, followed by Dishwashing at 10.9% and Fabric Care at 9.2%.
Direct reach maintained at 1.3 million outlets with total availability across 3.6 million outlets pan-India.

💡 Investors should monitor the company's margin recovery trajectory as it balances volume growth with commodity price pressures. While the volume-led growth is a positive sign of brand strength, the contraction in EBITDA margins requires a cautious outlook until price-cost parity is restored.

Jyothy Labs Q3 Results: Revenue Up 5.1% to ₹740 Cr with 7.2% Volume Growth

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 01:08 PM

Jyothy Labs reported a steady performance for Q3 FY26, with revenue reaching ₹740 crore, supported by a robust 7.2% volume growth. While value growth stood at 5.1% due to pricing pressures in the Dishwash segment, the company maintained a healthy operating EBITDA margin of 15%. Strong double-digit growth was observed in Household Insecticides (12.6%) and Personal Care (10.9%), while Fabric Care grew by 9.2%. Management highlighted a recovery in General Trade and continued strength in E-commerce and Quick Commerce channels.

Net Revenue for Q3 FY26 reached ₹740 crore, marking a 5.1% YoY value growth.
Volume growth outperformed value growth at 7.2%, indicating strong consumer demand.
Operating EBITDA stood at ₹110.7 crore with a margin of 15% for the quarter.
Household Insecticides and Personal Care segments grew by 12.6% and 10.9% in value respectively.
Dishwash segment saw 7% volume growth despite a 1.3% value decline due to strategic price cuts.

💡 Investors should take confidence in the strong volume growth and recovery in General Trade, which suggests market share gains. Monitor the company's ability to improve value growth as pricing stabilizes in the coming quarters.

Jyothy Labs Q3 Net Profit Dips 7.2% YoY to ₹81.1 Cr; Revenue Up 5.1%

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 12:55 PM

Jyothy Labs reported a modest 5.1% YoY increase in revenue to ₹739.61 crore for the quarter ended December 31, 2025. However, net profit declined by 7.2% YoY to ₹81.12 crore, primarily due to higher material costs and margin pressure in core segments like Fabric Care and Dishwashing. A notable positive was the Household Insecticides segment, which significantly narrowed its losses to ₹0.27 crore from ₹10.21 crore in the previous year. Overall, the results reflect a challenging quarter with rising expenses offsetting revenue gains.

Revenue from operations grew 5.1% YoY to ₹739.61 crore compared to ₹703.71 crore in Q3 FY25.
Net profit for the quarter fell 7.2% YoY to ₹81.12 crore, down from ₹87.41 crore.
Fabric Care segment revenue rose to ₹350.93 crore, but segment profit decreased to ₹67.71 crore from ₹71.58 crore YoY.
Household Insecticides segment showed recovery, reducing losses to ₹0.27 crore from a loss of ₹10.21 crore YoY.
Total expenses increased to ₹645.50 crore, driven by higher cost of materials consumed at ₹353.52 crore.

💡 Investors should be cautious as the profit decline indicates margin pressure despite revenue growth. Monitor the company's ability to manage raw material costs and the continued turnaround in the Household Insecticides business.

Jyothy Labs Schedules Q3FY26 Earnings Conference Call for February 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Feb 2026, 05:00 PM

Jyothy Labs Limited has announced a conference call for analysts and investors on February 9, 2026, at 4:00 PM IST. The call is intended to discuss the company's un-audited financial results for the quarter and nine months ended December 31, 2025. Management will provide insights into the financial performance and the strategic outlook for the company. This routine interaction allows investors to gain clarity on operational trends and management's future expectations.

Conference call set for February 9, 2026, at 16:00 IST following Q3FY26 results.
Discussion will cover financial performance for the quarter and nine months ended Dec 31, 2025.
Universal dial-in numbers are +91 22 6280 1144 and +91 22 7115 8045.
Coordinated by ICICI Securities with international toll-free access for major global hubs.

💡 Investors should attend or review the transcript to understand management's perspective on raw material costs and demand recovery. Pay close attention to updates regarding the 'way forward' and growth guidance.

Jyothy Labs Submits SEBI Compliance Certificate for Quarter Ended December 31, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 12:21 PM

Jyothy Labs Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by MUFG Intime India Private Limited, confirms that securities received for dematerialization during the quarter ended December 31, 2025, have been processed. It further verifies that the security certificates were mutilated and cancelled after due verification. This is a standard administrative filing required by Indian regulatory authorities to ensure the integrity of the shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Issued by Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited.
Confirms that dematerialized securities are listed on BSE and NSE where earlier shares were listed.
Verification and cancellation of physical certificates completed within prescribed SEBI timelines.
Confirms the name of depositories substituted in the register of members as registered owners.

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial results for fundamental performance indicators.

Jyothy Labs to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Dec 2025, 04:48 PM

Jyothy Labs Limited has announced the closure of its trading window for designated persons starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the quarter and nine months ending December 31, 2025. The window will remain closed until 48 hours after the financial results are officially released to the public. This is a standard regulatory procedure for listed companies to ensure fair trading practices.

Trading window closure begins on Thursday, January 1, 2026.
Closure pertains to the financial results for the third quarter and nine months ending December 31, 2025.
The window will reopen 48 hours after the results are made public.
Restriction applies to all designated persons and their immediate relatives as per the Company's Code of Conduct.

💡 This is a routine regulatory announcement and does not require any immediate action. Investors should look out for the upcoming Q3 FY26 earnings date to assess the company's financial performance.

View All JYOTHYLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In FY 2024-25, Fabric Care grew 5.0% (44% of revenue), Dishwashing grew 3.7% (34% of revenue), Household Insecticides declined 6.5% (7% of revenue), Personal Care declined 0.9% (11% of revenue), and Others grew 10.8% (4% of revenue). For H1 FY26, the company reported 1% value growth and 3.2% volume growth.

Geographic Revenue Split

Not disclosed in available documents, though the company maintains a pan-India presence with 23 manufacturing facilities and a strong focus on rural-driven growth.

Profitability Margins

Gross margin for H1 FY26 stood at 48%, a contraction from 50.8% in H1 FY25 due to input cost pressures. PAT margin for FY24 was 13.3% (INR 369.3 Cr on INR 2,767.2 Cr revenue).

EBITDA Margin

Operating EBITDA margin was 17.5% in FY25 (INR 500 Cr) compared to 17.4% in FY24 (INR 480 Cr). However, H1 FY26 saw a decline to 16.3% from 18.4% in the previous year due to higher operating costs and commodity fluctuations.

Capital Expenditure

The company is expected to remain debt-free as there are no major debt-funded capital expenditure plans. Cash and bank balances including investments increased to INR 757 Cr in FY25 from INR 618 Cr in FY24.

Credit Rating & Borrowing

CARE Ratings reaffirmed 'CARE AA; Stable' for long-term bank facilities (INR 250 Cr) and 'CARE A1+' for Commercial Paper (INR 100 Cr, later withdrawn as unutilized). The company operates with minimal finance costs of INR 6 Cr (FY25).

⚙️ Operational Drivers

Raw Materials

Key inputs include chemicals for detergents (Fabric Care), raw materials for soaps (Personal Care), and materials for insecticide coils. Specific commodity names like palm oil or LAB are not explicitly listed but are categorized as 'input costs' and 'commodities'.

Capacity Expansion

The company operates 23 state-of-the-art manufacturing facilities across India. Specific MTPA capacity figures or planned expansion units are not detailed in the provided text.

Raw Material Costs

Cost of Goods Sold (COGS) was INR 1,419 Cr in FY25, representing 49.8% of revenue, a slight increase of 1.1% YoY from INR 1,404 Cr.

Manufacturing Efficiency

The company focuses on economies of scale and productivity improvements to balance competitive pricing with profitability.

Logistics & Distribution

Advertisement and sales promotion costs were INR 240 Cr in FY25 (8.4% of net sales), used to support a distribution network reaching 1.2 million outlets directly.

📈 Strategic Growth

Expected Growth Rate

3.20%

Growth Strategy

Growth will be driven by volume-led expansion in rural markets using the van/moped model, scaling premium product launches, and leveraging digital/modern trade channels. The company aims to maintain an EBITDA margin of 16-17% through better mix management and scaling innovations.

Products & Services

Fabric whiteners, detergent powders, detergent bars, liquid detergents, dishwash bars, dishwash liquids, household insecticide coils, and personal care soaps.

Brand Portfolio

Ujala, Maxo, Exo, Henko, Pril, Margo, and Mr. White.

New Products/Services

Focus on liquid detergents (main growth driver for Fabric Care) and organic/natural products developed through R&D.

Market Expansion

Expansion of direct reach to 1.2 million outlets and total availability in 2.8 million outlets, focusing on rural-driven growth and modern trade/e-commerce.

Market Share & Ranking

Ujala commands a dominant position in the fabric care (whitener) segment; the company is a prominent pan-India FMCG player.

Strategic Alliances

Merged Jyothy Fabricare Services Ltd (JFSL) into the parent company and divested its 75% equity stake in Jyothy Kallol Bangladesh Limited (JKBL) as of March 25, 2025.

🌍 External Factors

Industry Trends

The FMCG sector is seeing a measured recovery driven by affordability and easing cost pressures, with a shift toward digital channels and premiumization.

Competitive Landscape

Operates in a fiercely competitive and price-sensitive industry dominated by MNCs with larger diversified portfolios.

Competitive Moat

Strong brand equity (Ujala), a massive distribution network (2.8m outlets), and a debt-free balance sheet provide a durable competitive advantage against smaller players.

Macro Economic Sensitivity

Highly sensitive to rural sentiment and inflation; a median population age of 27 and government financial inclusion initiatives are expected to drive exponential consumption growth.

Consumer Behavior

Increasing consumerism and rising aspirations among India's young population are driving demand for cleaning and hygiene solutions.

Geopolitical Risks

Global uncertainties continue to pose challenges to input costs and supply chain stability.

⚖️ Regulatory & Governance

Industry Regulations

Impacted by GST rate revisions (September 2025) which caused a 13% advantage for some distributors through input credit but disrupted short-term market flow.